-
6 days ago | 
thereader.com | Ryan Syrek
So many production companies have their logos in front of Fight or Flight, it is almost certain one is just straight-up laundering money, right? No one has yet invented a better way to cleanse ill-gotten gains than financing a Josh Hartnett action movie. That is a joke, just in case any of those 10-20 companies have good lawyers. This is all to say that, from the jump, Fight or Flight feels dodgy and suspect.
-
1 week ago | 
thereader.com | Ryan Syrek
Her character has no superpowers, but Florence Pugh is meta-human. Proof? She has survived acting opposite Timothée Chalamet twice and being directed as a woman by Christopher Nolan. Much will be made of how Thunderbolts* is some measure of a “return to form” for the Marvel Cinematic Universe (MCU) when it is simply further evidence that there is nothing that Pugh can’t improve. Make her the new National Security Advisor just to see what happens.
-
2 weeks ago | 
oncologynewscentral.com | Ryan Syrek
The U.S. Food and Drug Administration (FDA) rejected a new drug application (NDA) for TLX101-CDx (floretyrosine F18; Pixclara), an investigational imaging agent for glioma, according to an April 28 statement from the manufacturer, Telix Pharmaceuticals Limited.
-
3 weeks ago | 
thereader.com | Ryan Syrek
The “point” of Sinners, a rip-snorting vampire-centric music video, is not that “human beings are the real monsters.” The point of Sinners is a stake, driven through the heart of monsters of all-kinds, fanged or not. It is also that the most important thing in life is having a good time with the ones you love and also not summoning unholy hell-beasts by playing music that is simply too good. You are safest playing bad music.
-
1 month ago | 
thereader.com | Ryan Syrek
In the last week, I saw the movie Warfare, and I learned that someone who used to write here in the film section at The Reader died. Maddeningly, painfully, for the second time in less than a year, I find myself crafting something that is closer to a eulogy than it is a movie review. At least this one isn’t my hot take on an animated family film?
-
1 month ago | 
oncologynewscentral.com | Ryan Syrek |Youssef Rddad
The U.S. Food and Drug Administration (FDA) granted full approval to larotrectinib (Vitrakvi) for adults and children with NTRK fusion–positive solid tumors that are metastatic, unresectable, or have no other treatment options, drugmaker Bayer announced in an April 10 news release. Regulators based the latest decision on pooled data from the three single-group studies. These included results from the phase 1 LOXO-TRK-14001 trial, the phase 1/2 SCOUT trial, and the phase 2 NAVIGATE trial.
-
1 month ago | 
thereader.com | Ryan Syrek
Casting Michael Fassbender as a militant wife guy who hates liars is certainly a choice when the Wikipedia on his personal life is just right there. Ew.If it helps you endure that knowledge, Black Bag isn’t a sweet love song to marriage so much as a synth-jazz tune about loyalty.
-
1 month ago | 
patientpower.info | Ryan Syrek
On March 28, 2025, the U.S. Food and Drug Administration approved neoadjuvant durvalumab (Imfinzi) plus gemcitabine and cisplatin, followed by single-agent adjuvant durvalumab after radical cystectomy, for adults with muscle-invasive bladder cancer (MIBC). The FDA based the approval on results from the randomized, open-label, multicenter, phase 3 NIAGARA trial. The study enrolled 1,063 patients with MIBC who had not received prior systemic therapy and were eligible for radical cystectomy.
-
1 month ago | 
oncologynewscentral.com | Youssef Rddad |Ryan Syrek |Marcia Frellick
In March, the U.S. Food and Drug Administration (FDA) granted designations to several key oncology drugs for lung, blood, and pancreatic cancers, among others. Bexmarilimab for Myelodysplastic SyndromesOn March 3, Faron Pharmaceuticals announced that the FDA granted orphan drug designation to bexmarilimab, an investigational immunotherapy, for the treatment of patients with myelodysplastic syndromes (MDS).
-
1 month ago | 
thereader.com | Ryan Syrek
If you’re going to cast Paul Rudd, let him be funny. It’s not complicated. You have to actively prevent Paul Rudd from being funny. That is a decision you make. “Stop being funny, Paul Rudd,” you have to say. Paul Rudd is not funny in Death of a Unicorn. Very little is, actually. Will Poulter is funny. That isn’t a joke that Will Poulter is little. He is just the only thing in the movie that works. The rest of it is about as creative, fun, and free-spirited as a unicorn gif on a Tumblr blog.
